Dr. Timos Papagatsias’ Post

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> SK Bioscience takes majority stake in CDMO for $244M; Ex-Lonza CEO joins Cytiva: Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. SK Bioscience now has a 60% stake in the CDMO IDT Biologika after signing a deal with German pharma company Klocke, in a deal worth 339 billion Korean won ($244 million). Klocke will retain a 40% share in the CDMO, according to a Thursday release. Lonza’s former CEO Pierre-Alain Ruffieux is joining Cytiva as its new chief operating officer effective July, according to a Thursday release. This is a newly created role for Ruffieux, who left Lonza in September 2023. Ruffieux will be responsible for improving the customer experience and engagement at Cytiva. “[Ruffieux] brings unparalleled experience and a deep understanding of how suppliers positively impact the success of our pharmaceutical and biotechnology customers,” Cytiva’s CEO Chris Riley told Endpoints News in a statement. Evotec subsidiary, Just – Evotec Biologics, was chosen by the US Department of Defense for a multi-year project worth $39 million to develop monoclonal antibody technologies. The company will focus on decreasing the time it takes to develop and manufacture monoclonal antibodies so they can enter the clinic sooner, according to a Wednesday release. API manufacturer Veranova is investing $30 million to expand its antibody-drug conjugate facility in Devens, MA. The expansion will include a new process development lab as well as two new manufacturing suites, according to the company Thursday. ProBio opened its new plasmid DNA and viral vector manufacturing facility in Hopewell, NJ, on Tuesday. The 128,000 square-foot site will add to the company’s cell and gene therapy capabilities. Glenmark Pharmaceuticals is recalling 114 batches of 750 mg potassium chloride extended-release capsules because of “failed dissolution.” The capsules are for patients with low potassium in the blood. The production issue could cause hyperkalemia and cardiac arrest, according to a release Tuesday. Gilead’s Kite is testing Cellares’ automated cell therapy platform, dubbed the Cell Shuttle, in a proof of concept study, the companies said Thursday. Bristol Myers Squibb, Cabaletta and Lyell Immunopharma have also tapped Cellares for its automated tech. Charles River Laboratories has partnered with the Gates Institute at the University of Colorado Anschutz Medical Campus to make lentiviral vectors for the institute’s use for CAR-T cell therapies in blood cancers, according to a Tuesday release. Generic and biosimilar manufacturer Boston Oncology Arabia received a $35 million investment from investment firm TVM Capital Healthcare. The funding will be for the manufacturer to reach full… #lucidquest #genetherapy #celltherapy

If you missed the live session, the recorded webinar is now available! Key takeaways include unveiling how the XCell® ATF System achieves 2-10x higher titers for various biologics compared to traditional fed-batch processes. Dive into how top biopharma companies leverage ATF and TFDF technology to speed up market entry and increase facility capacity. Gain insights on linearly scaling from process development to clinical and commercial scale manufacturing.

𝐎𝐫𝐮𝐦 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐬 $𝟏 𝐁𝐢𝐥𝐥𝐢𝐨𝐧 𝐋𝐢𝐜𝐞𝐧𝐬𝐢𝐧𝐠 𝐃𝐞𝐚𝐥 𝐰𝐢𝐭𝐡 𝐕𝐞𝐫𝐭𝐞𝐱 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬 Orum Therapeutics Orum Therapeutics, a clinical-stage biotech company pioneering degrader-antibody conjugates (DACs), announced a global, multi-target license and option agreement with Vertex Pharmaceuticals (Nasdaq: VRTX) Vertex Pharmaceuticals. This agreement grants Vertex rights to use Orum’s Dual-Precision Targeted Protein Degradation (TPD²®) technology for discovering novel targeted conditioning agents for gene editing. Vertex will have the option to obtain a worldwide, exclusive license to research, develop, manufacture, and commercialize DACs using Orum’s TPD² technology. Orum will receive an upfront payment of $15 million and is eligible for additional option payments and milestones of up to $310 million per target for up to three targets, plus tiered royalties on future global sales. Vertex will handle all research, development, and commercialization efforts. "Vertex, a leader in innovative medicines and the first to receive FDA approval for a CRISPR/Cas9 gene-edited therapy, has chosen Orum’s TPD² technology to discover novel targeted conditioning agents," said Sung Joo Lee, Ph.D. SJ Lee, CEO and founder of Orum Therapeutics. "This agreement offers potential treatments for patients in a novel indication space with our leading targeted protein degradation approach." #Biotech #ProteinDegradation #GeneEditing #DACs #InnovativeMedicine #HealthcareInnovation #VertexPharmaceuticals #OrumTherapeutics #ClinicalTrials

CDMO - Cell and Gene Therapy (CGT) Represents the Next Phase of Growth ➡ The CDMO sector is still young, somewhat consolidated now, and growing in mid-to-high single digits ➡ We see this trend to continue driven by biopharma industry’s rising appetite to outsource production, in the backdrop of an increasingly complex manufacturing process, the need from relatively smaller biotechs for an experienced manufacturing partner to scale quickly while avoiding large capital outlays   ➡ Looking forward, we see the most organic growth for CDMOs to come from cell/gene therapy, with investment/M&A in the space increasing and the development pipeline strengthening ------------------------------------------------------------------------------------ Ready to leverage strategic intelligence to drive your CDMO growth strategy? We offer competitive intelligence monitoring services in key therapeutic areas with earnings call analyses, conference highlights, pipeline asset review, and strategic recommendation to make you stay ahead of the curve. Let us know your perspectives & challenges, and we will get you covered. Write us at bhabesh.panigrahi@eos-intelligence.com #genetherapy #cellandgenetherapy #pharmaceuticals #consulting #marketresearch #innovation #biopharma #biotech #future #growth #fda #pipeline #pharmamanufacturing #cmo #cdmo #biopharmaceuticals #eosintelligence #perspectives #strategy #intelligence #leadership Kemwell Biopharma WuXi Biologics Catalent Pharma Solutions Samsung Biologics Lonza Patheon MolMed now part of AGC Biologics BioNTech SE

Thoughts on this? >> Gordian Biotechnology Introduces High-Throughput In Vivo Screening Platform to Discover Therapies and Better ... - BioSpace >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharmaceutical #healthcare #pharma #competitivemarketing

Thoughts on this? >> CRISPR Therapeutics Stock (NASDAQ:CRSP): Will It Take Off Anytime Soon? - TipRanks.com - TipRanks >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #healthcare #pharmaceutical #competitivemarketing #biotech

Mirus sold again?? Interesting to see Gamma Bio sell off Mirus Bio asset to Merck KGaA. This is a company with transfection reagents that has been around the market for a long time. Originally bought by Roche in ~2008, parts of it were sold to Arrowhead three years later. The IP has been split up a few times. Most recently, it was acquired by Gamma Bio, a KKR-backed rollup that set out in 2019. Transfection reagents, particularly those of the GMP variety are of increasing importance for producing viruses (of multiple flavors) and other cell-based products. This, traditionally, was a space PolyPlus owned as one of the only vendors offering a GMP transfection reagent. PolyPlus was also recently transacted on with Sartorius acquiring them for $2.6B! A bit surprising to see Gamma selling off just Mirus at this point in the rollup, but perhaps the price was right given other happenings in the market. We expect to see no slow down in PE-backed life science roll ups as the market continues to heat up. Key will be differentiated, high-quality assets that solve real pain points in bioprocessing / manufacturing. Want to discuss this or other market developments? Reach out! #pharma #investing #drugdevelopment https://lnkd.in/g3kgn9sJ

Thoughts on this? >> Cencora's Lung-I Cheng: 'Cell and gene is becoming a very competitive space' - BioPharma-Reporter.com >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #biotech #pharmaceutical #pharma #competitivemarketing

Thoughts on this? >> CRISPR Therapeutics Stock (NASDAQ:CRSP): Will It Take Off Anytime Soon? - TipRanks.com - TipRanks >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #biotech #competitivemarketing #healthcare

Thoughts on this? >> Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV ... - GlobeNewswire >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #healthcare #pharma #competitivemarketing